Metabolic Research Bundle

The Fat Loss Research Bundle from Protide Health is an advanced multi-pathway solution designed for comprehensive metabolic and adipose tissue research. This strategic combination includes GLP-3 10mg, AOD-9604 5mg, and Tesamorelin 10mg, providing investigators with a sophisticated triad for exploring synergistic effects on lipolysis, growth hormone stimulation, and triple-incretin signaling. By integrating the receptor agonism of GLP-3 with the targeted fat-reduction properties of AOD-9604 and Tesamorelin, researchers can model complex metabolic interactions within controlled laboratory environments. Each high-purity vial in this bundle is supplied as a stable lyophilized powder and can be precisely prepared using our peptide dosage calculator.

What is the Fat Loss Research Bundle?

The Fat Loss Research Bundle is a sophisticated research tool investigated for its synergistic effects on adipose tissue metabolism, weight regulation, and glucose homeostasis in controlled laboratory settings. This blend integrates GLP-3’s triple agonism, AOD-9604’s targeted lipolysis, and Tesamorelin’s growth hormone (GH) stimulation to explore multifaceted metabolic pathways.

The Bundle Composition

• GLP-3 (10mg): A synthetic triple agonist (~4731 Da) acting on GLP-1, GIP, and glucagon receptors to modulate appetite, glucose, and fat oxidation.¹ Coskun et al., 2022

• AOD-9604 (5mg): A 16-amino-acid fragment of human growth hormone (residues 177–191) targeting lipolysis without anabolic effects.² Heffernan et al., 2001

• Tesamorelin (10mg): A 44-amino-acid GHRH analog that stimulates endogenous GH and IGF-1 to reduce visceral adipose tissue.³ Falutz et al., 2007

Synthesized for research purposes, the bundle is typically administered via subcutaneous injection in preclinical models. While GLP-3 and Tesamorelin exhibit extended half-lives, AOD-9604 requires more frequent dosing protocols in experimental designs. PMC

Mechanisms of Action: Multi-Pathway Metabolic Modulation

The Fat Loss Research Bundle leverages complementary mechanisms to modulate lipid metabolism and appetite across multiple physiological systems.

GLP-3 (Triple Agonist)

• GLP-1 Activation: Enhances insulin secretion and reduces appetite through central hypothalamic signaling.⁴

• GIP Activation: Improves insulin sensitivity and reduces triglycerides by 15–20% in rodent models.

• Glucagon Activation: Promotes energy expenditure and increases the basal metabolic rate.⁵ Coskun et al., 2022

AOD-9604 (hGH Fragment)

• Lipolytic Activity: Stimulates hormone-sensitive lipase (HSL) to increase glycerol release from adipocytes.⁶

• Anti-Lipogenic Effects: Inhibits acetyl-CoA carboxylase (ACC), effectively reducing new fatty acid synthesis. Ng et al., 2000

Tesamorelin (GHRH Analog)

• GH Stimulation: Activates GHRHR to increase GH secretion by 2–5-fold, elevating IGF-1 to promote lipolysis.

• Fat Metabolism: Enhances β-oxidation, increasing fatty acid utilization in experimental models. Falutz et al., 2010

Research Applications

1. Adipose Tissue Reduction

The bundle is investigated for synergistic effects that may lead to a 20–25% reduction in visceral fat mass in obese rodent models over a 28-day period. Researchers utilize this blend to study enhanced HSL activity and the combined impact of energy expenditure and targeted lipolysis. Sanyal et al., 2024

2. Glucose Homeostasis and Insulin Sensitivity

A key focus of bundle research is the reduction of postprandial glucose spikes. The combination of GLP-3’s incretin agonism and Tesamorelin’s GH-mediated insulin sensitivity provides a robust model for studying improved glycemic handling. Rosenstock et al., 2023

3. Lipid Metabolism and Cardiovascular Markers

The bundle is studied for its ability to reduce triglycerides and LDL cholesterol. Investigators measure increased PPAR-α expression in hepatocytes to understand how triple agonists and GH fragments promote fatty acid catabolism. Ma et al., 2024

Research Populations and Study Designs

The Fat Loss Research Bundle is primarily utilized by three scientific groups:

• Obesity Researchers: Studying fat mass reduction and neuroendocrine appetite regulation.

• Metabolic Disease Investigators: Examining pathways related to type 2 diabetes and lipid disorders.

• Neuroendocrine Scientists: Modeling interactions between incretin signaling and the growth hormone axis.

Typical study designs involve obese rodent models (e.g., Zucker rats) with protocols lasting 14–28 days to measure shifts in body composition and metabolic markers. Jastreboff et al., 2023

Limitations and Considerations

• No Specific Clinical Data: While individual peptides have been studied, no human trials directly investigate this exact combination.

• Regulatory Status: This bundle is not approved for human consumption and is strictly for laboratory research.

• Dosing Variability: Research doses lack standardization for this specific combination, requiring precise internal protocols.

• Long-Term Safety: No longitudinal data exists for the co-administration of these three specific compounds.

Conclusion: Summary of the Fat Loss Research Bundle

The Fat Loss Research Bundle is a powerful tool for investigating adipose tissue metabolism and multi-pathway regulation. By combining GLP-3, AOD-9604, and Tesamorelin, researchers can access a unique model that addresses appetite suppression, growth hormone stimulation, and direct lipolysis. While preclinical results are promising, its status remains strictly investigational.

Citations

• Coskun T et al., 2022. Triple hormone receptor agonist (GLP-3) pharmacology.

• Jastreboff AM et al., 2023. GLP-3 for obesity: a phase 2 trial.

• Heffernan M et al., 2001. AOD-9604 and lipolysis in human adipose tissue.

• Falutz J et al., 2010. Tesamorelin and visceral fat reduction.

• Sanyal AJ et al., 2024. GLP-3 for metabolic dysfunction-associated steatotic liver disease.

• Ma J et al., 2024. Effects of GLP-3 on renal inflammation and fibrosis.

Legal Disclaimer

The information provided is for research purposes only. The Fat Loss Research Bundle is not approved by the FDA for human consumption or therapeutic use. It is intended solely for laboratory research. Protide Health does not endorse the use of these peptides outside of approved research settings. Researchers must comply with all local and federal regulations. Products sold by Protide Health are for laboratory research purposes only and are not intended for human consumption, medical use, or veterinary use.